Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Donatello Gemma"'
Autor:
Carlo Signorelli, Maria Alessandra Calegari, Michele Basso, Annunziato Anghelone, Jessica Lucchetti, Alessandro Minelli, Lorenzo Angotti, Ina Valeria Zurlo, Marta Schirripa, Mario Giovanni Chilelli, Cristina Morelli, Emanuela Dell’Aquila, Antonella Cosimati, Donatello Gemma, Marta Ribelli, Alessandra Emiliani, Domenico Cristiano Corsi, Giulia Arrivi, Federica Mazzuca, Federica Zoratto, Maria Grazia Morandi, Fiorenza Santamaria, Rosa Saltarelli, Enzo Maria Ruggeri
Publikováno v:
Current Oncology, Vol 30, Iss 6, Pp 5456-5469 (2023)
Background: Patients with refractory mCRC rarely undergo third-line or subsequent treatment. This strategy could negatively impact their survival. In this setting, regorafenib (R) and trifluridine/tipiracil (T) are two key new treatment options with
Externí odkaz:
https://doaj.org/article/afc24ec0fba644d393d93c2ccdec9fdd
Autor:
Roberta Grande, Clara Natoli, Fabrizio Ciancola, Donatello Gemma, Arianna Pellegrino, Ida Pavese, Carlo Garufi, Luigi Di Lauro, Domenico Corsi, Diego Signorelli, Isabella Sperduti, Giada Cortese, Emanuela Risi, Federica Morano, Domenico Sergi, Carlo Signorelli, Enzo Maria Ruggeri, Germano Zampa, Marco Russano, Teresa Gamucci
Publikováno v:
PLoS ONE, Vol 11, Iss 7, p e0157751 (2016)
Colorectal cancer patients have a median age of incidence >65years although they are largely under-represented in phase-III trials. This large population contains patients unfit for treatment, those suitable for monotherapy or for doublets and the im
Externí odkaz:
https://doaj.org/article/97d78b69a6a840ab918650c0ca13b318
Autor:
Roberta Grande, Domenico Corsi, Raffaello Mancini, Donatello Gemma, Fabrizio Ciancola, Isabella Sperduti, Lorena Rossi, Agnese Fabbri, Maria G Diodoro, Enzo Ruggeri, Germano Zampa, Sara Bianchetti, Teresa Gamucci
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e80188 (2013)
BACKGROUND: Adjuvant chemotherapy (AC) in Stage II Colon Cancer (CC) is still under debate. Choice should be based on patients and disease characteristics. According to guidelines AC should be considered in high-risk T3N0 patients. No data are availa
Externí odkaz:
https://doaj.org/article/2b69bdaaf7ae41258c9ac1bdb8fa48b4
Autor:
Ruggeri, Carlo Signorelli, Maria Alessandra Calegari, Michele Basso, Annunziato Anghelone, Jessica Lucchetti, Alessandro Minelli, Lorenzo Angotti, Ina Valeria Zurlo, Marta Schirripa, Mario Giovanni Chilelli, Cristina Morelli, Emanuela Dell’Aquila, Antonella Cosimati, Donatello Gemma, Marta Ribelli, Alessandra Emiliani, Domenico Cristiano Corsi, Giulia Arrivi, Federica Mazzuca, Federica Zoratto, Maria Grazia Morandi, Fiorenza Santamaria, Rosa Saltarelli, Enzo Maria
Publikováno v:
Current Oncology; Volume 30; Issue 6; Pages: 5456-5469
Background: Patients with refractory mCRC rarely undergo third-line or subsequent treatment. This strategy could negatively impact their survival. In this setting, regorafenib (R) and trifluridine/tipiracil (T) are two key new treatment options with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::0b6a6ee4665224edd61eb0c3e2f78da7
Autor:
Carlo Signorelli, Federica Zoratto, Donatello Gemma, Rosa Saltarelli, Maria Grazia Morandi, Roberta Grande, Gian Paolo Spinelli, Salvatore De Marco, Isabella Sperduti, Mario Giovanni Chilelli, Anna Ceribelli, Enzo Maria Ruggeri
Publikováno v:
Journal of the National Comprehensive Cancer Network. 20:CLO22-084
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af5f58b244070046695304d23a000663
https://doi.org/10.6004/jnccn.2021.7125
https://doi.org/10.6004/jnccn.2021.7125
Autor:
Roberta Grande, Federica Zoratto, Mario Giovanni Chilelli, Isabella Sperduti, Salvatore De Marco, Maria Grazia Morandi, R. Saltarelli, Carlo Signorelli, Anna Ceribelli, Donatello Gemma, Enzo Maria Ruggeri, Gian Paolo Spinelli
Publikováno v:
Anticancer Research. 41:2553-2561
Background/aim Regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have have been shown to improve overall survival in patients with refractory metastatic colorectal cancer. The aim of our study was to evaluate the efficacy and safety profiles of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b89cd6a6b448f9d761b09c7d32e5e5be
https://doi.org/10.21873/anticanres.15033
https://doi.org/10.21873/anticanres.15033
Autor:
Signorelli, Carlo, Marta, Schirripa, Mario Giovanni Chilelli, Maria Alessandra Calegari, Michele, Basso, Annunziato, Anghelone, Jessica, Lucchetti, Alessandro, Minelli, Lorenzo, Angotti, Cristina, Morelli, Emanuela, Dell'Aquila, Cosimati, Antonella, Donatello, Gemma, Emiliani, Alessandra, Domenico, Corsi, Mazzuca, Federica, Zoratto, Federica, Maria Grazia Morandi, Santamaria, Fiorenza, Rosa, Saltarelli, Enzo Maria Ruggeri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a848917016aeab5d37206bf4fe16f00f
Autor:
Federica Marmorino, Lisa Salvatore, Sara Delfanti, Giuseppe Tonini, Emanuela Dell'Aquila, Gianluca Masi, Gabriella Fontanini, Luca Boni, Samantha Di Donato, Carlotta Antoniotti, Sabina Murgioni, Giuseppe Aprile, Sara Lonardi, Chiara Cremolini, Francesca Bergamo, Giacomo Allegrini, Alfredo Falcone, Beatrice Borelli, Donatello Gemma, Cristina Granetto, Marta Schirripa, Elisa Sensi, Mariaelena Casagrande
Publikováno v:
European Journal of Cancer. 109:175-182
Background Alternating induction and maintenance phases is a common strategy in metastatic colorectal cancer (mCRC). Metronomic chemotherapy (metroCT) may represent a well-tolerated chemotherapy backbone for maximising bevacizumab effect during maint
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be76b537c82757768b7c849345c341e5
https://doi.org/10.1016/j.ejca.2018.12.028
https://doi.org/10.1016/j.ejca.2018.12.028
Autor:
B. Giuseppina, Paolo Tralongo, Chiara Carlomagno, A. Colombo, M. Mare, Donatello Gemma, M. Biglietto, G. Bruera, Lorenzo Antonuzzo, G. Tonini, F. Cappuccio, Silvana Leo, G. Buccafusca, Vincenzo Formica, Stefano Cordio, Vincenzo Montesarchio
Publikováno v:
Annals of Oncology. 31:S110-S111
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a12be1bd195c5ab90b38cdfca75fd737
https://doi.org/10.1016/j.annonc.2020.04.148
https://doi.org/10.1016/j.annonc.2020.04.148
Autor:
Domenico Corsi, Donatello Gemma, Chiara Cremolini, Lisa Salvatore, Carlotta Antoniotti, Maria Laura Mancini, Lorenzo Marcucci, Giuseppe Aprile, Giuseppe Tonini, Alfredo Falcone, Giovanni Gerardo Cardellino, Francesca Bergamo, Emanuela Dell'Aquila, Sara Lonardi, Luca Boni, Vittorina Zagonel, Gianluca Masi, Gabriella Fontanini, Luigi Coltelli, Cristiana Lupi, Federica Marmorino, Francesca Di Fabio, Roberta Grande, Claudia Mescoli, Monica Ronzoni
Importance The combination of a triple-drug chemotherapy regimen with an anti–epidermal growth factor receptor (EGFR) agent as a first-line treatment of metastatic colorectal cancer (mCRC) showed promising activity along with safety concerns in sin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::023b1895b4721527ebb569962c24b69c
http://hdl.handle.net/11568/917104
http://hdl.handle.net/11568/917104